Apr 30,2015

Insulet Reports First Quarter 2015 Financial Results

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three months ended March 31, 2015. First quarter 2015 revenue decreased 11% to $61.2 million, compared with $69.2 million in the first quarter of 2014.

View Analyst & Ambassador Comments
Go to original news
May 21,2015

Eli Lilly invests in smartphone-connected insulin pen startup

San Diego, California-based Companion Medical, a stealthy medical device startup developing a Bluetooth-connected insulin pen and connected app, has closed its second round of funding, led by Eli Lilly and Company. The funding amount was not disclosed.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
May 01,2015

Nemaura Medical to Present at the 2015 Marcum Microcap Conference

Nemaura Medical Inc. (OTC BB: NMRD), a leading developer of minimally-invasive transdermal diagnostic technologies, announced today that Dr. D F Chowdhury, CEO, and Bashir Timol, Commercial Director, will be presenting at the 2015 Marcum Microcap Conference, which will take place May 27th to May 28th at the Grand Hyatt Hotel in New York City.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 01,2015

Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT® System at the Marcum Microcap Conference, New York

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing the sugarBEAT® CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 03,2015

BD Announces Results for 2015 Second Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015, representing a decrease of 1.0 percent from the prioryear period, or an increase of 4.9 percent on a foreign currency-neutral basis.

View Analyst & Ambassador Comments
Go to original news
May 04,2015

BD to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015, at 11:40 a.m. EDT.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 06,2015

Senseonics and Rubin Medical to Partner in Scandinavia to Commercialize New CGM Product

Senseonics, Incorporated, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, and Rubin Medical, a market leader in insulin pump distribution, today announced that they’re collaborating to commercialize the new Senseonics® Continuous Glucose Monitoring System in Scandinavia. The collaboration focuses on an exclusive distribution agreement of the Senseonics’ CGM system in Sweden, Norway and Denmark.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
May 13,2015

BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart™ Technology to Enhance the Use of Insulin Pumps

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmart™ technology. Insulin infusion sets connect the insulin pump to the body. The new product is BD’s first within the diabetes infusion set category.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
May 14,2015

LabStyle Innovations Receives Health Canada Approval for Commercialization of the Dario Diabetes Management Solution

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, has announced today that it has been granted Health Canada approval to market and sell Dario™ in Canada through their exclusive distributor in Canada Auto Control Medical Inc. ("ACM"). ACM is a Canadian leader in the category of medical devices for home use, and has successfully launched several blood glucose monitoring systems into the Canadian market over the years. Health Canada is Canada's federal department responsible for helping Canadians maintain their health and the Health Canada approval is a major milestone representing the first sales of Dario in North America.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
May 15,2015

LabStyle Innovations Announces 2015 First Quarter Results

LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, reported its financial and operational results for the three-month period ended March 31, 2015 and provided an update on recent corporate achievements. LabStyle's billings for the first quarter of 2015 amounted to approximately $141,000 compared to approximately $61,000 in the previous quarter and approximately $4,000 in the first quarter of 2014. This includes product shipments to distributors and direct customers as well as services provided in respect to LabStyle's patient management software platform launch as part of the partnership with Maccabi Healthcare.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES